Establishment of a biobank for research into the role of the intestinal and oral microbiome in the development of diseases of the digestive tract

Establishment of a biobank for research into the role of the intestinal and oral microbiome in the development of diseases of the digestive tract - ColoBAC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038707

Enrollment

1200

Registered

2026-01-28

Start date

2019-07-16

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alterations and diseases of the digestive tract/gastrointestinal system (e.g. in the context of diseases corresponding to ICD-10 dialogue such as K51, K50, C18 or E66) and axis from the intestine (microbiome) to peripheral organs (e.g. in the context of diseases corresponding to ICD-10 dialogue such as K58) K51 K50 C18 E66 K58

Interventions

Group 1: Patients with diseases or abnormalities of the digestive tract/digestive tract associated functions (e.g., IBD, polyps, CRC, metabolic alterations, pancreatic cancer, etc.) are sampled as fol

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who have a disease of the gastrointestinal system, who are suspected of having a disease of the gastrointestinal system, and/or who require endoscopic examination (colonoscopy and/or esophagogastroscopy) for further clarification, or who are presenting for an endoscopic check-up or preventive examination.

Exclusion criteria

Exclusion criteria: - Inability to consent to the study - Contraindication to biopsy sampling - Patients in reduced general condition (ECOG > 2)

Design outcomes

Primary

Measure	Time frame
The primary purpose of the biobank is to conduct research into diseases of the digestive tract as well as functional changes to the gastrointestinal system and the role of the intestinal and oral microbiome in this context (e.g., chronic inflammatory bowel disease, tumor diseases, metabolic disorders).	—

Secondary

Measure	Time frame
Exemplary secondary endpoints that can be addressed using data from the biobank: - Preventive and diagnostic usability of microbiome signatures for the early detection of gastrointestinal diseases - Identification of factors that disrupt the microbiome (e.g., medication, lifestyle, diet) in the context of the research questions - Significance of clinical metadata, lifestyle, and epidemiological data on the development of corresponding diseases	—

Measure

Time frame

Exemplary secondary endpoints that can be addressed using data from the biobank: - Preventive and diagnostic usability of microbiome signatures for the early detection of gastrointestinal diseases - Identification of factors that disrupt the microbiome (e.g., medication, lifestyle, diet) in the context of the research questions - Significance of clinical metadata, lifestyle, and epidemiological data on the development of corresponding diseases

—

Countries

Germany

Contacts

Public ContactMoritz Middelhoff

TUM Klinikum

moritz.middelhoff@mri.tum.de00498941408313

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026